TRANSMEDICS GROUP INC (TMDX) Stock Fundamental Analysis
NASDAQ:TMDX - Nasdaq - US89377M1099 - Common Stock - Currency: USD
Taking everything into account, TMDX scores 5 out of 10 in our fundamental rating. TMDX was compared to 189 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and the financial health of TMDX get a neutral evaluation. Nothing too spectacular is happening here. TMDX shows excellent growth, but is valued quite expensive already.
1. Profitability
1.1 Basic Checks
TMDX had positive earnings in the past year.
TMDX had a positive operating cash flow in the past year.
In the past 5 years TMDX reported 4 times negative net income.
TMDX had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
With an excellent Return On Assets value of 4.41%, TMDX belongs to the best of the industry, outperforming 82.01% of the companies in the same industry.
With an excellent Return On Equity value of 15.51%, TMDX belongs to the best of the industry, outperforming 92.06% of the companies in the same industry.
TMDX's Return On Invested Capital of 3.98% is fine compared to the rest of the industry. TMDX outperforms 74.60% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.41% | ||
| ROE | 15.51% | ||
| ROIC | 3.98% |
ROA(3y)-4.07%
ROA(5y)-12.78%
ROE(3y)-7.35%
ROE(5y)-22.97%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
TMDX has a Profit Margin of 8.03%. This is amongst the best in the industry. TMDX outperforms 82.01% of its industry peers.
Looking at the Operating Margin, with a value of 8.49%, TMDX is in the better half of the industry, outperforming 76.72% of the companies in the same industry.
The Gross Margin of TMDX (59.36%) is comparable to the rest of the industry.
In the last couple of years the Gross Margin of TMDX has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 8.49% | ||
| PM (TTM) | 8.03% | ||
| GM | 59.36% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.32%
GM growth 5Y0.21%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), TMDX is destroying value.
The number of shares outstanding for TMDX has been increased compared to 1 year ago.
The number of shares outstanding for TMDX has been increased compared to 5 years ago.
TMDX has a better debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 4.73 indicates that TMDX is not in any danger for bankruptcy at the moment.
TMDX has a Altman-Z score of 4.73. This is in the better half of the industry: TMDX outperforms 76.72% of its industry peers.
A Debt/Equity ratio of 2.23 is on the high side and indicates that TMDX has dependencies on debt financing.
TMDX has a Debt to Equity ratio of 2.23. This is amonst the worse of the industry: TMDX underperforms 83.60% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.23 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 4.73 |
ROIC/WACC0.49
WACC8.2%
2.3 Liquidity
A Current Ratio of 8.30 indicates that TMDX has no problem at all paying its short term obligations.
TMDX has a better Current ratio (8.30) than 88.89% of its industry peers.
TMDX has a Quick Ratio of 7.52. This indicates that TMDX is financially healthy and has no problem in meeting its short term obligations.
With an excellent Quick ratio value of 7.52, TMDX belongs to the best of the industry, outperforming 89.95% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 8.3 | ||
| Quick Ratio | 7.52 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 500.00% over the past year.
TMDX shows a strong growth in Revenue. In the last year, the Revenue has grown by 82.74%.
The Revenue has been growing by 79.64% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)500%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
Revenue 1Y (TTM)82.74%
Revenue growth 3Y144.36%
Revenue growth 5Y79.64%
Sales Q2Q%48.21%
3.2 Future
The Earnings Per Share is expected to grow by 49.75% on average over the next years. This is a very strong growth
TMDX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 21.08% yearly.
EPS Next Y47.95%
EPS Next 2Y50.7%
EPS Next 3Y44.08%
EPS Next 5Y49.75%
Revenue Next Year26.11%
Revenue Next 2Y23.29%
Revenue Next 3Y20.96%
Revenue Next 5Y21.08%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 87.30, the valuation of TMDX can be described as expensive.
Compared to the rest of the industry, the Price/Earnings ratio of TMDX indicates a somewhat cheap valuation: TMDX is cheaper than 66.14% of the companies listed in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 24.83, TMDX is valued quite expensively.
With a Price/Forward Earnings ratio of 51.76, TMDX can be considered very expensive at the moment.
Based on the Price/Forward Earnings ratio, TMDX is valued a bit cheaper than the industry average as 68.25% of the companies are valued more expensively.
The average S&P500 Price/Forward Earnings ratio is at 20.94. TMDX is valued rather expensively when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 87.3 | ||
| Fwd PE | 51.76 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of TMDX indicates a somewhat cheap valuation: TMDX is cheaper than 65.08% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 73.17 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates TMDX does not grow enough to justify the current Price/Earnings ratio.
TMDX's earnings are expected to grow with 44.08% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.82
PEG (5Y)N/A
EPS Next 2Y50.7%
EPS Next 3Y44.08%
5. Dividend
5.1 Amount
No dividends for TMDX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
118.73
+7.23 (+6.48%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners115.59%
Inst Owner Change-6.57%
Ins Owners3.16%
Ins Owner Change18.89%
Market Cap4.02B
Analysts81.18
Price Target119.85 (0.94%)
Short Float %26.8%
Short Ratio7.68
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-21.72%
Min EPS beat(2)-59.86%
Max EPS beat(2)16.42%
EPS beat(4)3
Avg EPS beat(4)244.45%
Min EPS beat(4)-59.86%
Max EPS beat(4)957.84%
EPS beat(8)6
Avg EPS beat(8)130.01%
EPS beat(12)9
Avg EPS beat(12)91.53%
EPS beat(16)10
Avg EPS beat(16)64.35%
Revenue beat(2)1
Avg Revenue beat(2)0.42%
Min Revenue beat(2)-7.28%
Max Revenue beat(2)8.12%
Revenue beat(4)3
Avg Revenue beat(4)6.85%
Min Revenue beat(4)-7.28%
Max Revenue beat(4)13.34%
Revenue beat(8)7
Avg Revenue beat(8)13.08%
Revenue beat(12)11
Avg Revenue beat(12)20.74%
Revenue beat(16)13
Avg Revenue beat(16)16.32%
PT rev (1m)1.84%
PT rev (3m)5.96%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-5.33%
EPS NY rev (1m)0%
EPS NY rev (3m)2.88%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)3.01%
Revenue NY rev (1m)0%
Revenue NY rev (3m)2.93%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 87.3 | ||
| Fwd PE | 51.76 | ||
| P/S | 9.1 | ||
| P/FCF | N/A | ||
| P/OCF | 82.3 | ||
| P/B | 17.57 | ||
| P/tB | 18.69 | ||
| EV/EBITDA | 73.17 |
EPS(TTM)1.36
EY1.15%
EPS(NY)2.29
Fwd EY1.93%
FCF(TTM)-2.39
FCFYN/A
OCF(TTM)1.44
OCFY1.22%
SpS13.05
BVpS6.76
TBVpS6.35
PEG (NY)1.82
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.41% | ||
| ROE | 15.51% | ||
| ROCE | 5.04% | ||
| ROIC | 3.98% | ||
| ROICexc | 7.27% | ||
| ROICexgc | 7.52% | ||
| OM | 8.49% | ||
| PM (TTM) | 8.03% | ||
| GM | 59.36% | ||
| FCFM | N/A |
ROA(3y)-4.07%
ROA(5y)-12.78%
ROE(3y)-7.35%
ROE(5y)-22.97%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.32%
GM growth 5Y0.21%
F-Score6
Asset Turnover0.55
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.23 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 8.9 | ||
| Cap/Depr | 656.67% | ||
| Cap/Sales | 29.38% | ||
| Interest Coverage | 3.32 | ||
| Cash Conversion | 85.24% | ||
| Profit Quality | N/A | ||
| Current Ratio | 8.3 | ||
| Quick Ratio | 7.52 | ||
| Altman-Z | 4.73 |
F-Score6
WACC8.2%
ROIC/WACC0.49
Cap/Depr(3y)951.97%
Cap/Depr(5y)615.69%
Cap/Sales(3y)34.99%
Cap/Sales(5y)23.68%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)500%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
EPS Next Y47.95%
EPS Next 2Y50.7%
EPS Next 3Y44.08%
EPS Next 5Y49.75%
Revenue 1Y (TTM)82.74%
Revenue growth 3Y144.36%
Revenue growth 5Y79.64%
Sales Q2Q%48.21%
Revenue Next Year26.11%
Revenue Next 2Y23.29%
Revenue Next 3Y20.96%
Revenue Next 5Y21.08%
EBIT growth 1Y240.24%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year184.98%
EBIT Next 3Y78.84%
EBIT Next 5Y66.36%
FCF growth 1Y50.91%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y474.6%
OCF growth 3YN/A
OCF growth 5YN/A